The total return over the past 12 months is -84.29% vs. +16.94% for the S&P 500. So far it's up -72.25% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (84.29%) | (68.96%) | N/A | N/A | N/A | N/A |
| Total Return CAGR | (84.29%) | (68.96%) | N/A | N/A | N/A | N/A |
| Revenue CAGR | N/A | (71.84%) | (36.87%) | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Virax Biolabs Group Limited (VRAX)
| Year | Start price | End price | VRAX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.65 | $2.40 | (72.25%) | +14.51% | (86.76%) |
| 2025 | $56.25 | $8.65 | (84.62%) | +17.72% | (102.34%) |
| 2024 | $36.50 | $56.25 | +54.11% | +24.89% | +29.22% |
| 2023 | $182.50 | $36.50 | (80.00%) | +26.19% | (106.19%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
